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In 2003, expenditure on diabetes, the fourth lead-
ing cause of death in Taiwan, consumed more
than US$320 million.1 Improvement in the qual-
ity of diabetes care is critical, both for the sake of
patients and to lower healthcare costs. However,
previous studies have suggested poor adherence to
practice standards, unsatisfactory glycemic control
and a high prevalence of diabetic complications
in Taiwan.2–4
Nonadherence and poor glycemic control
could be related to patient-, provider- or healthcare
system-based issues.5 Different service provisions
by generalists and specialists could result in varia-
tions in the quality of diabetes care. Several stud-
ries have shown better processes of care, superio
rglycemic control, and better cost-effectiveness o
yfewer complications in diabetes care provided b
diabetes specialists.5–15 However, other studies
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reported no meaningful differences in outcomes
of diabetes care provided by different physician
specialists.12,16,17
Comparisons of the quality of diabetes care
provided by different specialty groups could have
been influenced by patient characteristics, physi-
cian factors, organizational variations or insurance-
program differences. Unlike most other countries,
the National Health Insurance (NHI) program
enrolls 96% of people and contracts 93.8% of
the medical institutions in Taiwan.18 This unique
comprehensive nationwide medical insurance pro-
gram minimizes barriers to medical care. With ac-
creditation as one of the leading centers for clinical
service, teaching and research, the quality of dia-
betes care at National Taiwan University Hospital
(NTUH) is expected to be of a high standard in
Taiwan.19 Since neither the NHI nor the NTUH
sets regulations for diabetes care referral, patients
can freely access physicians of different special-
ties according to their own preference. At NTUH,
the majority of diabetes patients are under the
care of endocrinologists (EN), other specialists
in internal medicine (internists, IM) or family
medicine physicians (generalists, FM). Whether
or not physician specialty has an influence on
the quality of diabetes care in such a medical
center is an interesting topic. To our knowledge,
no previous report has discussed the use of an-
tidiabetes drugs in patients cared for by physi-
cians of different specialties. This retrospective
study was conducted to evaluate the influence of
physician specialty on the use of antidiabetes
medications. With consideration of patient case-
mix and physician characteristics, this study also
evaluated the quality of diabetes care, both in
terms of process and outcomes, provided by dif-
ferent physician specialists.
Methods
Study design and population
This retrospective medical chart review study 
was approved by the NTUH Research Ethics
Committee. In 2002, 12,023 diabetes patients
twho had visited outpatient clinics (OPD) a
NTUH more than four times were identified.
One-tenth of the patients were randomly sam-
pled out. The hospital computer database was re-
viewed. To minimize possible confounding, we
excluded patients with type 1 diabetes, patients
without antidiabetes drugs and those who had
been admitted to the emergency room or hospi-
tal within the study year. A total of 875 patients
ywho received antidiabetes medications regularl
at the clinics of EN, internists or generalists were
enrolled. No patients in the sample received
rantidiabetes medications from clinics of othe
physician specialties at NTUH. Demographic and
clinical data including sex, age, duration of dia-
betes, annual counts of OPD visits, medications
and comorbidities or complications of the re-
cruited patients were abstracted by chart review.
xAntidiabetes drugs were categorized into si
classes: insulin, sulfonylureas (glibenclamide,
gliclazide, glipizide, glimepiride, gliquidone),
biguanides (metfomin), α-glucosidase inhibitors
(acarbose), thiazolidinediones (rosiglitazone, pio-
glitazone) and nonsulfonylurea insulin secret-
agogues (repaglinide, nateglinide). The maximal
class-number of medications concurrently used
in each patient was calculated. Documented co-
rmorbidities or complications were recorded unde
tthe categories of cerebral vascular disease, hear
disease, hypertension, hyperlipidemia, renal dis-
rease and other systemic diseases (lung and live
diseases, malignancy, endocrinopathy, gastrointes-
tinal problems, hematology disease), neuropa-
thy, retinopathy and peripheral arterial disease
(including diabetic foot disease). The total num-
ber of comorbidities and complications for each
patient was calculated. The physician responsible
for individual patients’ every visit was identified.
Most of the recruited patients were under the
care of one particular physician. If a patient had
visited more than two physicians within a year,
the physician most frequently visited was re-
corded as the major care physician for that pa-
rtient. The relevant characteristics of the majo
care physician for the individual patient were
identified.
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Evaluation of the process and outcomes
of diabetes care
According to the diabetes care practice guidelines
set up by the Department of Health, Executive
Yuan20 and the quality-based payment program
implemented by the Bureau of National Health
Insurance (NHIB),21 tests of plasma glucose, gly-
cosylated hemoglobin A1C (HbA1C), urinalysis and/
or urine microalbumin, renal function test (RFT,
serum creatinine), liver function test (LFT, serum
alanine aminotransferase [ALT]), and plasma lipid
profile should be done at least once annually.
None of the studied patients was enrolled into the
NHI quality-based payment program. Previous
literature did not include adherence to LFT as an
indicator.5–17 We had demonstrated a high preva-
lence of abnormal liver function in diabetes pa-
tients and suggested adding LFT to the practice
guidelines for safety medication considerations.2
LFT is now recommended as one necessary dia-
betes care measure in the NHI quality-based pay-
ment program.21 We therefore included adherence
to LFT as one indicator in our analysis. In this
study, the process indicators were evaluated by
counting the annual frequency of those diabetic
care measures. Glucose measurement included
either fasting plasma glucose (FPG) or postpran-
dial plasma glucose (PPG). Self-monitored
blood glucose was not included in this study.
The lipid profile included total cholesterol (TC),
triglycerides (TG), high-density lipoprotein cho-
lesterol (HDL-C) and low-density lipoprotein
cholesterol (LDL-C). Urinalysis included urine
routine and urine microalbumin. When more
than one laboratory examination under the same
category was performed during one OPD visit, the
frequency of the examination in that category was
counted only once. Adherence to the measures
was considered to be positive when the examina-
tion was performed at least once within the year.
The adherence to fundus examination or electro-
cardiogram was not assessed in this study.
The outcome indicators included systolic blood
pressure (SBP), diastolic blood pressure (DBP)
and blood levels of HbA1C, FPG, PPG, TC, TG,
HDL-C and LDL-C. Blood pressure (BP) checkup
rdid not include home monitoring. Serum FPG o
RPPG level was measured using the TBA-120F
analyzer (Toshiba Corp., Tokyo, Japan) with the
HK-G6PD (hexokinase and glucose-6-phosphate
dehydrogenase) method. HbA1C was measured
using the Primus CLC 385 (Primus Corp., Kansas
City, MO, USA) with the high performance liquid
chromatography method. Serum creatinine, serum
ALT, TC, TG, HDL-C and LDL-C were measured
using the TBA-200 autoanalyzer (Toshiba Corp.)
with Jaffe’s method, JSCC transferable method, en-
zymatic method, enzymatic-colorimetric method,
direct and direct methods, respectively. Those
intermediate outcomes were analyzed using the
latest data in that year. Percentages of patients with
their BP, glycemic or lipid control achieving rec-
ommendations22 were also included as outcome
indicators.
Statistical analysis
Excel 7.0 for Windows and SAS 10.0 (SAS Institute
rInc., Cary, NC, USA) for Windows were used fo
data management and statistical analysis. Con-
tinuous variables are presented as mean ± stan-
dard deviation. The significance of the difference
for process or outcome indicators between dif-
ferent physician specialties was calculated by the
χ2 test for categorical variables and analysis of vari-
ance for continuous numerical variables. Process
rindicators of the IM and FM groups were furthe
compared to the EN group by logistic regression
analysis. The adherence to diabetes care measures
was a dependent variable (1: examination was per-
formed at least once in the year; 0: otherwise).
xPhysician characteristics and/or patient case-mi
were independent variables. The odds ratios (OR)
and the 95% confidence intervals (CI) were
calculated. Outcome indicators were compared
between groups by linear regression. The standard-
ized coefficients and 95% CI of the coefficients
were calculated. The statistical significance of lo-
gistic or linear regression was evaluated in three
different models. In model 1, regression analysis
was adjusted for case-mix factors (sex, age, duration
of diabetes, annual count of visits, insulin ther-
apy and number of comorbidities/complications).
ff fE ects o  physician specialty on diabetes care
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Table 1. Patient characteristics by physician specialty*
EN patients IM patients FM patients p
†
(n = 385) (n = 320) (n = 170) EN vs. IM IM vs. FM EN vs. FM Overall
Male gender (%) 57.1 54.4 48.8 0.461 0.242 0.069 0.193
Age (yr) 60.0 ± 13.6 65.1 ± 11.4 62.1 ± 11.7 < 0.001 0.006 0.084 < 0.001
DM duration (yr) 10.3 ± 6.7 9.8 ± 6.6 8.8 ± 6.1 0.583 0.230 0.091 0.233
Annual visit counts 9.9 ± 4.4 9.1 ± 4.2 9.4 ± 3.4 0.016 0.502 0.160 0.039
Com-No 1.3 ± 1.3 2.1 ± 1.3 1.8 ± 1.3 < 0.001 0.003 < 0.001 < 0.001
Patient number (% of patients in each group) with comorbidities/complications
CVD 23 (6.0) 42 (13.1) 12 (7.1) 0.001 0.412 0.628 0.003
Heart disease 46 (12.0) 108 (33.8) 31 (18.2) < 0.001 < 0.001 0.048 < 0.001
Hypertension 168 (43.6) 238 (73.8) 110 (64.7) < 0.001 0.036 < 0.001 < 0.001
Hyperlipidemia 85 (22.1) 97 (30.3) 47 (27.7) 0.013 0.538 0.156 0.004
Renal disease 29 (7.5) 23 (7.2) 20 (11.8) 0.862 0.088 0.105 0.172
Neuropathy 27 (7.0) 29 (9.1) 27 (15.9) 0.316 0.024 0.001 0.004
Retinopathy 35 (9.1) 15 (4.7) 14 (8.2) 0.023 0.113 0.743 0.072
PAD 10 (2.6) 10 (3.1) 3 (1.8) 0.674 0.373 0.550 0.669
Other systemic 83 (21.6) 100 (31.3) 30 (17.7) 0.004 0.001 0.292 < 0.001
diseases
*Numerical variables are expressed as mean ± standard deviation; †calculated by χ2 test for categorical variables and by ANOVA for
numerical variables. EN = endocrinologist; IM = internal medicine; FM = family medicine; DM = diabetes mellitus; Com-No = numbers
of comorbidities/complications; CVD = cerebral vascular disease; PAD = peripheral arterial disease.
In model 2, regression analysis was adjusted for
the major care physician’s sex and age. Both case-
mix and physician characteristics were consid-
ered in model 3. A p value of less than 0.05 was
considered statistically significant.
Results
A total of 875 patients (477 men, 398 women)
with a mean age of 62.3 ± 12.7 years (range,
19–100 years) were enrolled in this study. The
mean duration of diabetes mellitus was 9.8 ± 6.6
years. The mean frequency of OPD visits during
the year was 9.5 ± 4.2. The numbers of patients
who were regularly treated by EN, IM and FM were
385, 320 and 170, respectively. Gender distribu-
tion and diabetes duration were not significantly
different among EN, IM and FM groups. Patients
in the EN group were younger. They had fewer
comorbidities/complications, but more OPD visits
than patients in the other two groups (Table 1).
The mean serum creatinine levels for patients of
EN, IM and FM were 1.1 ± 1.0 mg/dL (n = 170),
1.1 ± 1.0 mg/dL (n=182) and 0.9 ± 0.3 mg/dL (n=
r117), respectively. The mean serum ALT levels fo
patients of EN, IM and FM were 31.5 ± L35.3 U/
(n = 155), 38.4 ± 35.3 U/L (n = 147) and 32.5 ±
27.2 U/L (n = 100), respectively. Mean serum cre-
atinine and ALT levels were not statistically dif-
ferent among the different patient groups.
There were 13 EN, 39 internists and 18 gener-
alists enrolled in this study. The mean age of the
major care physicians was 48.0 ± 8.1, 46.1 ± 7.7
and 42.0 ± 6.4 years for EN, IM and FM groups,
respectively. The percentage of males in EN, IM
and FM physicians was 97.5%, 96.9% and 82.3%,
respectively.
 About 29% of the patients were treated with
a single oral hypoglycemic agent (OHA), 59.5%
were treated with more than two classes of OHAs,
5.4% were treated with insulin alone and 6.1%
were treated with a combination of OHA and in-
rsulin. For all patients, the maximum class-numbe
of drugs had significant correlations with the levels
of FPG, PPG and HbA1C (r = 0.202, 0.166, 0.213,
F.Y. Tseng, M.S. Lai
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Table 2. Antidiabetes drugs by physician specialty
EN patients IM patients FM patients p*
(n = 385) (n = 320) (n = 170) EN vs. IM IM vs. FM EN vs. FM Overall
Patient number (% of patients in each group) with drugs
Sulfonylureas 228 (59.2) 265 (82.8) 140 (82.4) < 0.001 0.898 < 0.001 < 0.001
Non-SU secretagogues 40 (10.4) 6 (1.9) 5 (2.9) < 0.001 0.448 0.003 < 0.001
Metformin 271 (70.4) 194 (60.6) 114 (67.1) 0.006 0.161 0.433 0.023
Thiazolidinediones 70 (18.2) 61 (19.1) 25 (14.7) 0.765 0.228 0.316 0.473
Acarbose 44 (11.4) 24 (7.5) 23 (13.5) 0.079 0.031 0.484 0.077
Insulin 78 (20.3) 14 (4.4) 8 (4.7) < 0.001 0.866 < 0.001 < 0.001
Class-numbers of drugs 1.9 ± 0.8 1.8 ± 0.7 1.9 ± 0.8 0.034 0.245 0.575 0.106
Patient number (% of patients in each group) with different medication patterns
OHA, one class 95 (24.7) 107 (33.4) 52 (30.6)
OHA, ≥ 2 classes 212 (55.1) 199 (62.2) 110 (64.7)
< 0.001 0.749 < 0.001 < 0.001
Insulin only 36 (9.4) 8 (2.5) 3 (1.8)
OHA and insulin 42 (10.9) 6 (1.9) 5 (2.9)
*Calculated by χ2 test for categorical variables and by ANOVA for numerical variables. EN = endocrinologist; IM = internal medicine; FM = family medi-
cine; Non-SU = nonsulfonylurea; OHA = oral hypoglycemic agent.
Note: Sulfonylureas included glibenclamide, gliclazide, glipizide, glimepiride, gliquidone. Non-SU insulin secretagogues included repaglinide and nateglinide.
Thiazolidinediones included pioglitazone and rosiglitazone.
respectively, all p < 0.001). The correlations re-
mained significant no matter whether it was the
EN, IM or FM group. The mean class-numbers 
of antidiabetes drugs did not differ among the
different patient groups. However, EN patients
had the highest rate of being prescribed insulin,
metformin, nonsulfonylurea insulin secretagogues
and the lowest rate of being given sulfonylureas
(Table 2).
The adherence rates to annual measures for
all the patients were as follows: glucose checkup
89.7%, HbA1C measurement 82.5%, urinalysis
48%, RFT 53.6%, lipid profile 69% and LFT
45.9%. The EN group had the highest adherence to
glucose checkup, HbA1C measure and urinalysis,
while patients in the FM group had the highest
adherence to annual RFT, lipid profile and LFT
(Table 3). The significance of the differences for
the adherence between IM and EN groups and
between FM and EN groups varied in different
models of logistic regressions (Table 4). However,
the differences in adherence to glucose, HbA1C
tests and urinalysis between the IM and EN groups
remained statistically significant regardless of 
adjustment for case-mix, physician characteristics
or both. The EN group also had persistently sig-
nificantly higher adherence to glucose checkup
and urinalysis than the FM group (Table 4).
Among those who had examinations within
the study year, the EN group had the highest fre-
quencies of glucose checkup, HbA1C testing and
urinalysis (Table 3). In the evaluation of the cor-
relation between the process and the intermediate
outcomes of diabetes care, we found that frequen-
cies of glucose or HbA1C testing had no correla-
tion with FPG or HbA1C tlevels, but more frequen
glucose testing correlated with lower PPG levels
(r = −0.16, p < 0.001).
tNot all patients had body weight, body heigh
or BP recorded in their medical charts. Body mass
rindex (BMI) and BP measurement in the study yea
were available in 68.6% and 77.7%, 62.2% and
84.8%, and 76.5% and 90.8% of the EN, IM and
FM patients, respectively. The mean levels of inter-
mediate outcomes for all the patients with avail-
able data were as follows: BMI 25.3 ± 3.6 kg/m2,
SBP 134.8 ± 16.3 mmHg, DBP 78.2 ± 9.5 mmHg,
HbA1C 7.3 ± 1.5%, FPG 8.47 ± 3.08 mmol/L, PPG
ff fE ects o  physician specialty on diabetes care
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Table 4. Adjusted odds ratio (95% confidence interval) for performing diabetes care measures in patients cared for by internists
or generalists compared to patients cared for by endocrinologists
Model 1* Model 2† Model 3‡
IM vs. EN FM vs. EN IM vs. EN FM vs. EN IM vs. EN FM vs. EN
Glucose checkup 0.13§ 0.22§ 0.23|| 0.31¶ 0.25¶ 0.18¶
(0.04–0.41) (0.06–0.78) (0.12–0.44) (0.13–0.73) (0.06–0.94) (0.04–0.83)
HbA1C testing 0.19|| 0.58 0.21|| 0.40¶ 0.23§ 0.39
(0.09–0.40) (0.23–1.48) (0.12–0.36) (0.19–0.85) (0.08–0.64) (0.10–1.45)
Urinalysis 0.31|| 0.48¶ 0.20|| 0.34|| 0.32|| 0.36¶
(0.18–0.53) (0.27–0.87) (0.14–0.29) (0.21–0.58) (0.16–0.63) (0.15–0.84)
RFT 1.66 3.09|| 1.53¶ 1.79¶ 1.54 2.08
(0.99–2.80) (1.68–5.70) (1.07–2.20) (1.08–2.99) (0.80–2.97) (0.89–4.90)
Lipid profile 0.82 1.25 0.84 1.29 0.89 1.14
(0.46–1.44) (0.65–2.41) (0.58–1.22) (0.74–2.25) (0.44–1.81) (0.46–2.84)
LFT 1.6 2.30§ 1.19 1.29 1.28 1.7
(0.96–2.69) (1.28–4.11) (0.83–1.71) (0.78–2.13) (0.66–2.48) (0.74–3.93)
*Model 1: adjusted for patient case-mix; †Model 2: adjusted for physician characteristics; ‡Model 3: adjusted for patient case-mix and physician character-
istics; §p < 0.005; ||p < 0.001; ¶p < 0.05. Odds ratios and statistical significance were calculated by logistic regression. IM = internal medicine; EN = endocri-
nologist; FM = family medicine.
Note: Adherence to exams is dependent variable (1 = with annual exam; 0 = otherwise). Patient and physician characteristics are independent variables.
12.04 ± 4.56 mmol/L, TC 5.25± 1.14 mmol/L, TG
2.05±2.44mmol/L, HDL-C 1.22 ± 0.30 mmol/L
and LDL-C 2.92 ± 0.79 mmol/L. The percentage
of patients with BP < 130/80 mmHg was 19.6%,
having HbA1C level < 7.0% was 49.3%, and with
serum LDL-C level < 2.6 mmol/L was 33.5%.
fPatients cared for by EN had the lowest levels o
FPG and PPG, and patients cared for by generalists
F.Y. Tseng, M.S. Lai
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Table 3. Patient numbers (%) having exams during the year and annual counts of exams (among those who had received
annual exam) in different patient groups
EN patients IM patients FM patients p*
(n = 385) (n = 320) (n = 170) EN vs. IM IM vs. FM EN vs. FM Overall
Patient number (% of patients in each group) having exams during the year
Glucose checkup 370 (96.1) 263 (82.2) 152 (89.4) < 0.001 0.035 0.002 < 0.001
HbA1C measure 357 (92.7) 224 (70.0) 141 (82.9) < 0.001 0.002 < 0.001 < 0.001
Urinalysis 254 (66.0) 98 (30.6) 68 (40.0) < 0.001 0.037 < 0.001 < 0.001
RFT 170 (44.2) 182 (56.9) 117 (68.8) < 0.001 0.010 < 0.001 < 0.001
Lipid profile 261 (67.8) 210 (65.6) 133 (78.2) 0.543 0.004 0.013 0.013
LFT 155 (40.3) 147 (45.9) 100 (58.8) 0.129 0.007 < 0.001 < 0.001
Mean annual count of examinations (patient number of those who had received annual examination)†
Glucose checkup 5.4 ± 2.7 (370) 3.3 ± 2.2 (263) 2.9 ± 1.7 (152) < 0.001 0.044 < 0.001 < 0.001
HbA1C measure 3.9 ± 2.1 (357) 2.4 ± 1.4 (224) 2.3 ± 1.1 (141) < 0.001 0.588 < 0.001 < 0.001
Urinalysis 3.9 ± 2.7 (254) 2.2 ± 2.2 (98) 1.5 ± 0.8 (68) < 0.001 0.006 < 0.001 < 0.001
RFT 1.5 ± 1.2 (170) 1.8 ± 1.6 (182) 1.4 ± 0.6 (117) 0.071 0.005 0.205 0.012
Lipid profile 2.2 ± 1.8 (261) 2.2 ± 1.3 (210) 2.0 ± 1.0 (133) 0.661 0.104 0.089 0.194
LFT 2.1 ± 1.8 (155) 2.2 ± 1.6 (147) 1.7 ± 1.0 (100) 0.803 0.008 0.028 0.038
*Calculated by χ2 test for categorical variables and by ANOVA for numerical variables; †numerical variables are expressed as mean ± standard deviation.
EN = endocrinologist; IM = internal medicine; FM = family medicine; RFT = renal function test; LFT = liver function test.
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Table 5. Intermediate outcomes by physician specialty
EN patients IM patients FM patients p*
(n = 385) (n = 320) (n = 170) EN vs. IM IM vs. FM EN vs. FM Overall
Intermediate outcomes† (patient number with data available)
SBP (mmHg) 133.7 ± 16.4 (293) 137.2 ± 16.1 (259) 132.9 ± 16.2 (154) 0.013 0.009 0.601 0.011
DBP (mmHg) 77.6 ± 9.7 (293) 78.8 ± 9.3 (259) 78.6 ± 9.6 (154) 0.136 0.810 0.309 0.296
HbA1C (%) 7.3 ± 1.5 (357) 7.3 ± 1.5 (224) 7.5 ± 1.6 (141) 0.694 0.221 0.310 0.445
FPG (mmol/L) 8.22 ± 2.73 (370) 8.57 ± 3.43 (260) 8.92 ± 3.20 (152) 0.147 0.309 0.011 0.048
PPG (mmol/L) 11.00 ± 4.26 (223) 12.91 ± 4.71 (198) 12.58 ± 4.50 (109) < 0.001 0.547 0.002 < 0.001
TG (mmol/L) 2.04 ± 3.13 (253) 2.06 ± 1.65 (208) 2.06 ± 1.98 (132) 0.952 0.995 0.958 0.997
TC (mmol/L) 5.24 ± 1.18 (259) 5.19 ± 1.06 (209) 5.37 ± 1.19 (133) 0.691 0.164 0.304 0.385
HDL-C (mmol/L) 1.26 ± 0.30 (83) 1.19 ± 0.31 (127) 1.22 ± 0.28 (65) 0.098 0.502 0.399 0.239
LDL-C (mmol/L) 2.94 ± 0.72 (77) 2.88 ± 0.79 (123) 3.13 ± 1.22 (12) 0.592 0.323 0.445 0.552
Patient number (% of patients with data available in each group) with optimal control
BP < 130/80 mmHg 63 (21.5) 40 (15.4) 35 (22.7) 0.068 0.063 0.766 0.107
HbA1C < 7.0% 181 (50.7) 108 (48.2) 67 (47.5) 0.560 0.897 0.522 0.754
FPG 5.0–7.2 mmol/L 120 (32.4) 82 (31.5) 40 (26.3) 0.813 0.263 0.169 0.377
PPG < 10.0 mmol/L 106 (47.5) 56 (28.3) 34 (31.2) < 0.001 0.592 0.005 < 0.001
TG < 1.7 mmol/L 146 (57.7) 111 (53.4) 71 (53.8) 0.350 0.939 0.462 0.597
HDL-C > 1.1 mmol/L 56 (67.5) 70 (55.1) 43 (66.2) 0.074 0.141 0.866 0.134
LDL-C < 2.6 mmol/L 26 (33.8) 40 (32.5) 5 (41.7) 0.855 0.521 0.593 0.813
*Calculated by χ2 test for categorical variables and by ANOVA for numerical variables; †numerical variables are expressed as mean ± standard deviation.
EN = endocrinologist; IM = internal medicine; FM = family medicine; SBP = systolic blood pressure; DBP = diastolic blood pressure; HbA1C = glycosylated
hemoglobin A1C; FPG = fasting plasma glucose; PPG = postprandial plasma glucose; TG = triglyceride; TC = total cholesterol; HDL-C = high-density
lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; BP = blood pressure.
had the lowest mean SBP (Table 5). Following ad-
justment for case-mix and physician characteris-
tics, the difference in SBP between groups became
statistically nonsignificant. In linear regression
analysis, EN patients had persistently significantly
better FPG control when compared to FM patients
regardless of adjustments for patient case-mix,
physician characteristics or both. EN patients also
had significantly better PPG control when com-
pared to IM patients. The differences in serum
HDL-C and LDL-C levels between the EN and FM
groups were originally nonsignificant, but the dif-
ferences became statistically significant in linear
regression analysis with full model adjustment
(Table 6).
Discussion
Suboptimal accountability for diabetes care in
Taiwan was first reported from a regional teaching
hospital in 1996.2 In that study, adherence rates to
HbA1C measure and urinalysis at diabetes patients’
first visits were reported to be 40.9% and 57.5%,
respectively.2 About 9.9% and 18.6% of the dia-
betes patients never received any HbA1C rtest o
urinalysis during a follow-up period of 3 years.2
Using year 2001 NHI Taipei Branch claims data,
the annual adherence rates to glucose checkup,
HbA1C measure, urinalysis, RFT, lipid profile
and LFT were reported to be 76.3%, 42.7%,
40.2%, 59.7%, 59.2% and 53.2%, respectively.4
yIn October 2001, in a bid to improve the qualit
of diabetes care, the NHIB implemented the
quality-based payment program for diabetes care.
We did not evaluate the influence of that pro-
gram because none of the studied patients were
recruited into that program. The adherence rates
to most of the diabetes care measures at NTUH
were higher than those previously reported.2,4,23
The mean HbA1C yand FPG levels in this stud
were also lower than those of 25 diabetes centers
in Taiwan.3 However, a failure to meet the rec-
ommended standards, such as low adherence to 
urinalysis or missing records for body weight 
or BP measures, was still noted. Our findings
suggest that there is a need to improve the quality
of diabetes care.
At NTUH, diabetes patients have free access
to physicians for their diabetes care. Patients of
internists usually have diseases other than dia-
betes. For convenience, most patients with other
systemic diseases preferred to be cared for by 
internists for their major diseases and to get 
their antidiabetes drugs from the internists at the
same time. Patients cared for by generalists usu-
ally had more, but relatively mild, diseases. The
“cluster” effect of patients with specific character-
istics to remain with physicians having specific
characteristics has been discussed before.17 In
our series, EN patients were younger and had
lower numbers of comorbidities/complications.
This observation suggests that younger diabetes
patients prefer to be cared for by EN. Trying to
enroll patients with the same disease severity, we
excluded patients who had visited emergency ser-
vices or who had been admitted to hospital. The
sex ratios, mean duration of diabetes, serum cre-
gatinine and ALT levels were not different amon
ggroups. To minimize possible bias originatin
from the heterogeneity of the patient population,
rwe further adjusted patient characteristics in ou
analysis.
In reviewing antidiabetes prescription pat-
terns, the tendency away from monotherapy with
insulins or sulfonylureas and toward combi-
nation therapies has been reported in the US
and in Stockholm.24,25 rThe use of OHAs othe
than sulfonylureas has increased rapidly.24–26 tI
was reported that improvement in metabolic and
F.Y. Tseng, M.S. Lai
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Table 6. Standardized coefficients (95% confidence interval) of intermediate outcomes in patients cared for by
internists or generalists compared to patients cared for by endocrinologists
Model 1* Model 2† Model 3‡
IM vs. EN FM vs. EN IM vs. EN FM vs. EN IM vs. EN FM vs. EN
SBP (mmHg) 0.01 −0.01 0.13§ −0.02 −0.03 −0.03
(−3.72–4.29) (−4.70–4.08) (0.10–6.98) (–5.47–3.50) (−6.16–4.19) (−7.56–4.88)
DBP (mmHg) 0.06 0.09 0.11§ 0.08 0.05 0.1
(−1.38–3.50) (−0.66–4.69) (0.04–4.04) (−0.50–4.49) (−2.01–3.93) (−1.24–5.89)
HbA1C (%) 0.11 0.08 −0.03 −0.01 0.13 0.06
(−0.07–0.75) (−0.15–0.70) (−0.38–0.22) (−0.43–0.37) (−0.09–0.94) (−0.40–0.84)
FPG (mmol/L) 0.13§ 0.15§ 0.06 0.10§ 0.12 0.18§
(0.05–1.62) (0.19–1.89) (−0.19–0.99) (0.05–1.68) (−0.28–1.79) (0.20–2.79)
PPG (mmol/L) 0.24⏐⏐ 0.21§ 0.22¶ 0.09 0.23§ 0.08
(0.80–3.65) (0.59–3.64) (0.16–3.20) (−0.34–2.56) (0.37–3.93) (−1.23–3.10)
TG (mmol/L) −0.03 0.12 −0.01 −0.03 −0.04 0.09
(−0.59–0.40) (−0.07–0.99) (−0.002–0.49) (−0.03–0.46) (−0.61–0.42) (−0.32–0.92)
TC (mmol/L) 0.01 0.10 −0.01 0.08 −0.01 0.15
(−0.29–0.32) (−0.09–0.57) (−0.28–0.24) (−0.09–0.57) (−0.41–0.36) (−0.06–0.88)
HDL-C (mmol/L) −0.02 −0.06 −0.10 0.02 0.09 0.26§
(−0.13–0.11) (−0.17–0.10) (−0.17–0.04) (−0.12–0.15) (−0.10–0.21) (0.01–0.37)
LDL-C (mmol/L) 0.15 0.15 −0.01 0.17 0.09 0.45¶
(−0.12–0.58) (−0.20–1.10) (−0.33–0.29) (−0.03–1.44) (−0.31–0.63) (0.97–3.41)
*Model 1: adjusted for patient case-mix; †Model 2: adjusted for physician characteristics; ‡Model 3: adjusted for patient case-mix and physician charac-
teristics; §p<0.05; ||p<0.005; ¶p<0.001. IM = internal medicine; EN = endocrinologist; FM = family medicine; SBP = systolic blood pressure; DBP = diastolic
blood pressure; HbA1C = glycosylated hemoglobin A1C; FPG = fasting plasma glucose; PPG = postprandial plasma glucose; TG = triglyceride; TC = total
cholesterol; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol.
Note: Standardized coefficients and statistical significance were calculated by linear regression.
cardiovascular outcomes of diabetes care was not
correlated with the simultaneously changed pre-
scription pattern.25 By linking pharmacy and labo-
ratory data, Wetzler and Snyder27 reported few
changes in therapy despite the large percentage of
patients with suboptimal control. To our knowl-
edge, the effect of physician specialty on prescrip-
tion pattern has never been discussed. In our
series, the mean maximum class-numbers of anti-
diabetes drugs did not differ among EN, IM or FM
patients. The maximum class-numbers of drugs
were significantly correlated with the levels of
FPG, PPG and HbA1C, regardless of patient group.
These findings might reflect the common response
of adding more drugs to overcome poor glycemic
control. EN prescribed insulin, metformin and
nonsulfonylurea insulin secretagogues more fre-
quently than internists and generalists. Since the
mean serum creatinine and ALT did not differ
among groups, we would like to infer, but con-
servatively, that physicians of different specialties
might have different preferences in prescribing
antidiabetes drugs. The true effects of physician
specialty on the targets of glycemic control and on
suboptimal glycemic control should be further
explored in future prospective studies.
Compatible with previous reports, our data
clearly showed that patients of EN had better 
adherence to diabetes care measures than patients
of internists or generalists. It has been said that
specialists may order excessive tests and provide
a higher cost style of care than generalists.6,11 The
mean annual frequencies of diabetes care measures
for the EN patients were still not as recommended.
Our data showed better, but not overutilized,
process of diabetes care provided by EN.
Zgibor et al13 reported a lower HbA1C in
patients with type 1 diabetes cared for by spe-
cialists. In our series, EN patients had the lowest
mean FPG and PPG, and highest percentage of
patients with PPG <10 mmol/L. The difference in
FPG levels between EN and FM groups and the dif-
ference in PPG levels between EN and IM groups
remained statistically significant even after full
model adjustment. The EN group had the highest
percentage of patients, though not statistically
significant, with HbA1C level < 7.0%. The adher-
ence to HbA1C measure was lower, especially in
the IM groups, than the adherence to glucose
checkup. The statistical significance of the differ-
ence in glycemic control indicators among EN,
IM and FM patients might, thus, be biased by in-
complete data in some patients. Moreover, in-
ternists or gen reralists who continued to monito
HbA1C might be more familiar with the diabetes
care practice guidelines than those who did not.
The difference in HbA1C among EN, IM and FM
groups might, therefore, be less significant than
the difference in glucose levels among groups.
Although not statistically significant in all indica-
tors of glycemic control, patients of EN did have
a tendency to achieve superior glycemic control
than patients of other specialists.
A previous study reported a potential bidirec-
tional relationship between glycemic control and
adherence at adolescence.28 Our analysis showed
no correlations between frequencies of glucose
and HbA1C testing with FPG and HbA1C levels.
However, more frequent glucose measures cor-
related with lowering PPG levels. Increasing fre-
quencies of testing might indicate the act to a
poor control, but not necessarily be linked to
changing therapy or improving outcome.27 The
ttrue effects of the intensive monitoring migh
not be shown clearly in this retrospective study.
The discrepancy in the correlations between FPG,
PPG and HbA1C with the frequencies of glucose
and HbA1C testing deserves further investigation
in a future prospective study.
It was reported that general practitioners who
are female or have ≤10 years of work experience
have better recordings of BP.12 Generalists, who
were female and younger, showed better perform-
ance than EN twith regard to BP and body weigh
recording in this study. Pellegrini et al29 reported
a higher risk for poor BP control by male physi-
cians and a lower risk for poor BP control by EN.
Other studies did not demonstrate the effects
of physician specialties on BP control.12,16,17 In
our series, the FM group had the lowest SBP.
However, the differences in BP control became
insignificant after adjustment for case-mix and
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physician characteristics. This result suggests that
there are no meaningful differences in BP control
for diabetes patients under the care of physicians
of different specialties.
Berardis et al10 reported better TC levels in 
patients cared for in diabetes OPD clinics. In our
series, the differences in HDL-C and LDL-C be-
tween the EN and FM groups were originally non-
significant, but the differences became statistically
significant after full model adjustment. Since pa-
tient numbers with HDL-C and LDL-C available
were small, we would like to be more cautious in
making conclusions from these findings.
Our study showed a significant effect of physi-
cian specialty on the process and the intermediate
glycemic outcomes of diabetes care. However, this
conclusion has several limitations. First, outcome
data were not available for patients who did not
receive examinations in the year. The analysis is
thus limited by incomplete data in some patients.
Second, not all indicators of glycemic control
showed similar statistically significant results.
Third, initial glycemic and BP levels were not ex-
tracted from medical records in this retrospective
study. We therefore cannot estimate the real im-
provement in glycemic and BP control contributed
by different physician specialties. Fourth, we did
not assess and adjust for physician attitudes and
beliefs. It has been reported that the personal at-
titudes and beliefs of the individual physician,
rather than physician specialty or setting of care,
influence metabolic control.30 Fifth, we did not
evaluate the influence of patients’ socioeconomic
status. Studies have reported that patients of lower
socioeconomic standing are less likely to receive
specialist care.5 Lower socioeconomic status is
also an important risk factor for nonutilization
of preventive services.5,13,31 Sixth, the adjustment
with numbers of comorbidities/complications
might not be enough to reflect the variation and
complexity of patients’ disease entities.
In conclusion, our analysis showed different
use of antidiabetes drugs among patients cared 
for by EN, internists and generalists. Our findings
highlight the effects of physician specialty on the
process and outcomes of diabetes care. We suggest
rconsistent education and further enhancement fo
improving the quality of diabetes care in Taiwan.
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